Our Business

Eurofins Group overview

Eurofins Scientific is an international life sciences company group that provides a unique range of analytical testing services to clients across multiple industries. The Group believes it is the global leader in food, environment, pharmaceutical, and cosmetic product testing, discovery pharmacology, forensics, advanced material sciences, and agroscience Contract Research services.

It is also one of the global independent market leaders in specific testing and laboratory services for genomics, in support of clinical studies, and in BioPharma Contract Development and Manufacturing. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing. With over 62,000 staff across a network of more than 1,000 independent companies in 62 countries generally specialized by the end client markets and operating in over 900 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as develop and carry out innovative clinical diagnostic testing services.

The Group’s objective is to provide customers with high-quality and innovative services and accurate results on time and, when requested, expert advice from its highly-qualified staff. Eurofins is committed to pursuing its dynamic growth strategy by expanding its technology portfolio and geographic reach. Through R&D and acquisitions, the Group draws on the latest biotechnology and analytical chemistry developments to offer its clients unique analytical solutions and an extensive range of testing methods. As one of the most innovative and quality-oriented international companies in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners worldwide.

Eurofins was founded by Dr. Gilles Martin in October 1987 with initially three employees. It went public in October 1997 on the Paris Stock exchange with 100 employees and celebrated its 30th anniversary in 2017 with 30 000 employees.

Since its IPO on the French stock exchange in 1997, Eurofins’ revenues have increased by 33% yearly (compound average). Eurofins is a member of the CAC 40 and Stoxx Europe Stoxx 600 indices.

Eurofins Strategy and Objectives

Eurofins' mission is to contribute to a safer and healthier world by providing our customers with innovative and high-quality laboratory, research, and advisory services while creating opportunities for our employees and generating sustainable shareholder value. Eurofins operates in a range of clearly defined markets that its leaders believe have high growth potential and where competition is generally still fragmented. Eurofins is structured as a decentralized network of independent companies. Leaders of each of the Group's businesses develop their strategy and business plans with their teams. Indeed, the Group does not operate under one single process but with several specific to each market in which subsidiary companies operate. In general, Eurofins companies and groups thereof, constituting regional or global business lines, employ all or a combination of the following to develop a unique offering for their clients and, as a result, build strong market positions and defendable and sustainable competitive advantage:

• Use advanced technologies supported by a high level of R&D and bespoke IT solutions;
• Deliver standardized, accredited services of high quality;
• Leverage Eurofins' growing global network of laboratories and service/product portfolio to generate scale effects (in particular top, line synergies from cross-selling services offered by other laboratories in the network) and position themselves as a first-choice provider based on innovation, quality, breadth, and depth of offering;
• Over time, they strive to become the number one or number two service provider in every niche laboratory testing market in which they operate.

Each laboratory strives for operational excellence and aspires to be the best partner for its clients by leveraging the Group's network capabilities. This can be achieved, for example, through sharing of know-how and best practices across continents, world-class IT infrastructure and bespoke IT solutions, integrated logistics, and significant investments in R&D and laboratory infrastructure to develop better and differentiated services.

By following this long-term focussed significant investment program, the leading and preferred provider has been achieved across many countries and market segments during the last 22 years.

The Group aims to grow through organic development (selling more to existing customers and attracting new customers) and selective acquisitions, facilitating access to new customers, geographic markets, technologies, and innovation.